Preventive Care Is Shifting, and Genetic Testing Is Part of the Reason

Photo Credit: jscreen.org

Preventive care has long followed a familiar structure where patients undergo routine screenings, clinicians monitor established biomarkers, and interventions are introduced when early signs of disease appear. While this model has improved outcomes through earlier detection, it remains largely reactive, only identifying disease after it has begun to develop.

That is changing due to genetic testing, which has become increasingly relevant as healthcare moves toward more individualized care.

Rather than identifying disease in its early stages, genetic screening allows for the identification of inherited risk before disease is present. This has implications for how care is planned, patients are monitored, and clinical decisions are made. In practice, it allows providers to move from responding to disease toward anticipating it.

Despite this, genetic testing has not yet been fully integrated into routine preventive care. The adoption of this technology has been uneven, often being limited to individuals with a strong family history or those referred by specialists. As a result, a significant portion of individuals with elevated genetic risk may remain unidentified.

The scientific basis for testing is well established. Variants in genes such as BRCA1 and BRCA2 are associated with increased lifetime risk for breast, ovarian, and other cancers. When identified early, these risks can inform changes in clinical management, including earlier screening, increased surveillance, and, in some cases, risk-reducing interventions.

The more persistent barriers have been structural.

Access to genetic testing has traditionally depended on referrals, proximity to specialists, and availability of genetic counseling. The latter remains a constraint, with a well-documented shortage of trained professionals in many regions. These limitations have contributed to the underuse of genetic testing, even as its clinical value has become clearer.

jscreen, a national nonprofit public health initiative, addresses these access barriers through at-home, saliva-based collection kits that allow individuals to complete testing outside of traditional clinical settings. Results are returned within a defined timeframe and paired with access to licensed genetic counselors through telehealth, allowing for interpretation and next-step planning.

This model reflects a growing emphasis on accessibility without removing clinical oversight. By combining remote testing with professional guidance, it attempts to close the gap between availability and usability, which has historically limited adoption.

Photo Caption: Dr. Matt Goldstein, MD/PhD, CEO of jscreen
Photo Credit: jscreen.org

“Genetic testing allows people to better understand their inherited risks and take action early, often before symptoms ever appear,” said Dr. Matt Goldstein, CEO of jscreen.

The integration of counseling into these models is a critical component. Genetic results are often probabilistic, not definitive. Variants of uncertain significance and risk markers require context to be clinically meaningful. Without appropriate guidance, the information may be misinterpreted or underutilized.

The scope of genetic testing has also expanded beyond hereditary cancer risk. Carrier screening represents a parallel application with implications for reproductive planning. Conditions such as Tay-Sachs disease, cystic fibrosis, and sickle cell disease are typically asymptomatic in carriers, making them difficult to identify without testing. When both partners carry the same gene, the risk of passing the condition to their children increases, creating a need for informed decision-making early in the planning process.

In this context, genetic testing functions not only as a clinical tool but as a planning tool that extends beyond the individual patient.

Its role in preventive care is not to replace existing screening protocols, but to complement them. Traditional screenings identify disease at an early stage. Genetic testing shifts the focus further upstream, identifying risk before disease develops. This allows for more personalized care strategies that can be adjusted over time.

For patients, the entry point remains relatively straightforward. Reviewing family health history, discussing potential testing with a provider, and considering whether additional information would influence future decisions are practical first steps. For some, testing may confirm low risk. For others, it may prompt earlier or more targeted interventions.

For clinicians and health systems, integration presents a more complex challenge. Expanding access must be balanced with the infrastructure required to support interpretation, counseling, and follow-up care. Without that support, increased availability alone may not translate into improved outcomes.

The broader trajectory, however, is clear. As healthcare continues to move toward personalized, data-informed models, genetic testing is likely to become a more routine component of preventive care.

Its value lies in its ability to inform decisions earlier in the disease timeline, when more options are available, and interventions may be more effective. In that sense, genetic testing represents a progression rather than a disruption. It extends the scope of preventive care, allowing both patients and providers to act with greater foresight, using information that remains consistent over time to guide decisions that shape long-term health.